[Fatal bleeding diarrhoea during dabigatran etexilate therapy]

Area of Science:

• Geriatric Medicine
• Pharmacology
• Nephrology

Background:

• Dabigatran etexilate is an anticoagulant used to prevent blood clots.
• Elderly patients often have reduced renal function, increasing drug level risks.
• Bleeding is a known complication of anticoagulant therapy.

Observation:

• A 77-year-old patient on dabigatran etexilate experienced a fatal bleeding event.
• The patient had impaired renal function, potentially exacerbated by diarrhea and dehydration.
• These factors likely contributed to elevated dabigatran levels and bleeding.

Findings:

• Fatal bleeding occurred in an elderly patient treated with dabigatran etexilate.
• Impaired renal function significantly increases bleeding risk in patients on this anticoagulant.
• Mild conditions like dehydration can precipitate renal impairment and bleeding.

Implications:

• Vigilance for renal function is crucial in elderly patients on dabigatran etexilate.
• Physicians should consider potential renal insults (e.g., dehydration) in this population.
• Case highlights the importance of individualized risk assessment for anticoagulation therapy.